CSO

OMB No. 0925-0001 and 0925-0002 (Rev. 03/2020 Approved Through 02/28/2023) BIOGRAPHICAL SKETCH Provide the following information for the Senior/key personnel and other significant contributors. Follow this format for each person. DO NOT EXCEED FIVE PAGES. NAME: Volkmann, Robert A. eRA COMMONS USER NAME (credential, e.g., agency login): POSITION TITLE: Chief Scientific Officer, BioPharmaWorks, LLC EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.) INSTITUTION AND LOCATION DEGREE (if applicable) Completion Date MM/YYYY FIELD OF STUDY Lafayette College, Easton, Pennsylvania University of Pittsburgh, Pittsburgh, PA Stanford University, Stanford, CA B.A. Ph.D. Post Doc 05/67 05/72 08/74 Chemistry Organic Chemistry Organic Chemistry A. Personal Statement I am a medicinal chemist with broad and extensive experience in drug discovery, particularly for neurological conditions. I have 34 years of experience as a medicinal chemist for Pfizer Global Research and Development, where I was actively involved in process chemistry, immunology, infectious disease, diabetes, neuroscience, natural product isolation, and developing new technologies for drug discovery. I have over 100 patents and publications and have given numerous scientific presentations. I am recognized widely for my experience and knowledge of drug discovery over all and pharmaceutical chemistry specifically. While in the neuroscience group from 1987 to 2009, my laboratory discovered a series of nNOS inhibitors for treatment of stroke, as well as novel glutamate antagonists, novel p-type calcium channel antagonists from venoms, novel neurotransmitter release enhancers, 5HT2A/SRI agents for the treatment of depression, and AMPA modulators for cognitive function improvement. My laboratory also prepared Englitazone, a PPAR gamma agonist for the treatment of diabetes, and Sulopenem, a potent broad spectrum penem antibacterial. In addition, I co-developed a systems-based approach, which is the first of its kind that enables multifactorial analysis of chemical and biological data for complex biological systems. This technology translates broad and heterogeneous preclinical and clinical information embedded in millions of study points into standardized information spectra to tackle otherwise intractable problems facing drug discovery scientists. I am currently Founder and CSO of BioPharmaWorks (BPW), which is currently working with ~35 biotech and pharmaceutical companies to enhance or lead particular drug discovery and development programs. In addition, BPW has drug discovery programs of its own to provide prodrug solutions to medical problems. I have led a chemistry effort at Cadent Therapeutics (formerly Mnemosyne Pharma & Luc Therapeutics), which is centered on discovery of allosteric modulators of subtypes of the NMDA receptor. Novartis licensed a compound from this work that is current completing Phase II trials. Another compound from these efforts is starting a Phase 1 trial for treatment of Schizophrenia. I currently lead chemistry discovery efforts at five other companies. I have enjoyed productive collaborations with many outstanding scientists, and I look forward to contributing to future projects B. Positions and Honors Positions 2015 - Present President and CSO of BioPharmaWorks, LLC 2011 - 2018 Vice President of Chemistry, Mnemosyne Pharmaceuticals (now Cadent Therapeutics) 2009 - 2017 Chief Scientific Officer, Systamedic Inc 1989 - 2009 Senior Research Fellow, Pfizer Global Research & Development 1985 - 1989 Research Advisor, Pfizer Global Research & Development 1982 - 1985 Principal Research Investigator, Pfizer Central Research 1978 - 1982 Senior Research Scientist, Pfizer Central Research 1974 - 1978 Research Scientist, Pfizer Central Research Honors 1971 - College of Arts and Sciences Distinguished Teaching Award, University of Pittsburgh 1972 - National Institute of Health Postdoctoral Fellowship 1994 - Chairman: Natural Products Gordon Conference 2000 - Pfizer Central Research Achievement Award 2002 - Pfizer Award for Scientific Excellence in Chemistry 2008 - Chair-Organic Division of the American Chemical Society 2009 - American Chemical Society Fellow C. Contributions to Science 1. Pfizer Drug Discovery. The work of my neuroscience group at Pfizer resulted in a series of nNOS inhibitors for treatment of stroke. We also generated novel glutamate antagonists, p-type calcium channel antagonists from venoms, neurotransmitter release enhancers, 5HT2A/SRI agents for the treatment of depression, and modulators of AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) to treat cognitive function impairment. Other work included development of Englitazone, a peroxisome proliferator-activated receptor-gamma (PPAR) agonist for treatment of diabetes, and